This week, the biotech space witnessed significant milestones, including FDA approvals, oncology drug acquisitions, and collaborations. Positive clinical trial results were reported across multiple therapeutic areas, including radiographic and non-radiographic axial spondyloarthritis, microcystic lymphatic malformations, pulmonary arterial hypertension, and obesity. Here's a closer look at the details. FDA Approvals & Rejections Armata Pharma Secures FDA QIDP Designation for AP-SA02 Armata Pharmaceuticals, ...

On February 17, 2026, Hedge fund BVF disclosed a new position in Disc Medicine (NASDAQ:IRON), acquiring 650,000 shares. What happened According to a recent SEC filing dated February 17, 2026, BVF reported a new position in Disc Medicine, Inc. during the fourth quarter, acquiring 650,000 shares. The quarter-end value of the position stood at $51.62 million, reflecting both the purchase and share price movement over the period. What else to know This was a new position for BVF, with Disc Medicine repres ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (MARK ONE) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 Commission file number: 001-39630 MOONLAKE IMMUNOTHERAPEUTICS (Exact Name of Registrant as Specified in Its Charter) (IRS Employer Identification No.) Cayman Islands 98-1711963 (State or Other Jurisdiction of Incorporation) ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECUR ...

This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace. If you like what you read here and would like to subscribe to, I'm currently offering a two-week free trial period for subscribers to take advantage of. My service offers a deep-dive analysis of many pharmaceutical companies. The Biotech Analysis Central SA marketplace is $49 per month, but for those who sign up for the yearly plan will be able to take advantage of a 33. ...

PresentationMatthias BodenstedtChief Financial Officer Good morning, good afternoon. Thank you so much for joining our Investor Day today, MoonLake Immunotherapeutics. My name is Matthias Bodenstedt, I'm the CFO of the company. And I'm sitting here on the right, Dr. Jorge Santos da Silva, our Chief Executive Officer; and Professor Kristian Reich, our Chief Scientific Officer. Together, we are very excited to walk you through a number of updates about the company. I will start with a very brief introduction, ...

Panama officially scraps CK Hutchison contracts, handing canal ports to Maersk | ReutersSkip to main content[Exclusive news, data and analytics for financial market professionalsLearn more aboutRefinitiv]Item 1 of 4 A drone view shows Panama Ports Company (PPC) after Panama's Official Gazette published a court ruling formally annulling Hong Kong's CK Hutchison Holdings concessions for two ports along its strategic canal, after ruling late January the contracts violated the constitution, in Panama City, Pana ...

Core Insights - The article discusses the promising results of the Phase 2 S-OLARIS trial for sonelokimab, indicating its potential as an effective treatment for axial spondyloarthritis [2][3] - MoonLake Immunotherapeutics has a strong cash position, which is expected to support its operations into the second half of 2027 [4] - The stock of MoonLake is currently experiencing short-term weakness but has a Buy Rating from analysts with varying price targets [6][8] Clinical Trial Results - In the S-OLARIS trial, 81% of patients treated with sonelokimab achieved a clinically meaningful response at Week 12, showing significant improvement in disease parameters [2] - The trial confirmed sonelokimab's ability to reduce inflammation and osteoblast activity, suggesting a rapid onset of action [2] - Biomarker-controlled data indicated a reduction in key inflammatory mediators in patients, with a consistent safety profile compared to previous trials [3] Financial Position - MoonLake ended Q4 with $394 million in cash and equivalents, alongside $75 million from a recent equity raise, providing a cash runway into H2 2027 [4] - The company amended its debt facility with Hercules Capital, allowing for a drawdown of $25 million and up to $400 million in non-dilutive funds for future needs [4] Stock Performance and Analyst Consensus - The stock is trading 9.8% below its 20-day SMA and 4.1% below its 100-day SMA, indicating short-term weakness [6] - The stock is currently 67.2% below its 52-week high, with key resistance at $20.00 and support at $15.00 [8] - Analysts have a Buy Rating on the stock with an average price target of $40.00, with recent price actions showing a 9.70% increase to $20.59 in premarket trading [8]

MoonLake Immunotherapeutics (NasdaqCM:MLTX) 2026 Investor Day February 23, 2026 08:00 AM ET Company ParticipantsJorge Santos da Silva - CEOJulian Harrison - Managing DirectorKristian Reich - Co-Founder and CSOMatthias Bodenstedt - CFOYun Zhong - SVP of Equity ResearchConference Call ParticipantsBrian Abrahams - Biotechnology Analyst and Global Sector Head of Healthcare ResearchKaveri Pohlman - Managing Director and Senior Equity Research AnalystPrakhar Agarwal - Senior Biotech AnalystThom Smith - Senior Man ...

Investor Day February 23rd, 2026 MoonLake Immunotherapeutics © 2026 | Proprietary | MoonLake TX Welcome to our Investor Day Date: February 23rd, 2026 Time: 8.00 am EST Agenda | Topic | Sub-topics | Speaker | Timing | | --- | --- | --- | --- | | Introduction | Welcome | Matthias | 10 mins | | | MLTX & SLK summary | | | | | Key points for the session | | | | axSpA update | axSpA market update | Kristian | 20 mins | | | S-OLARIS program overview | | | | | Efficacy & safety overview | | | | HS and FDA | FDA upd ...

Exhibit 99.1 MoonLake Announces Positive Topline Results from its Phase 2 Clinical Trial of Sonelokimab in Axial Spondyloarthritis and Reports 2025 Financial Results ZUG, Switzerland, February 22, 2026 – MoonLake Immunotherapeutics (NASDAQ:MLTX) ("MoonLake" or the "Company"), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory diseases, today announces topline results from the S-OLARIS Phase 2 trial of SLK in patients with radiographic and non-radiographic axSpA ...